证券代码：300261 证券简称：雅本化学 公告编号：2024-041 雅本化学股份有限公司 关于召开2024年第二次临时股东大会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据雅本化学股份有限公司（以下简称"公司"）第五届董事会第十八次（临 时）会议的决定，公司将于 2024 年 5 月 31 日召开公司 2024 年第二次临时股东 大会，现将有关事项通知如下： 一、本次会议的基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：经公司第五届董事会第十八次（临时）会议 审议通过，决定召开 2024 年第二次临时股东大会，召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间 现场会议时间：2024 年 5 月 31 日（星期五）下午 14:30 网络投票时间：2024 年 5 月 31 日 通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 5 月 31 日上午 9:15-9:25，9:30-11:30 和下午 13:00- ...

证券代码：300261 证券简称：雅本化学 公告编号：2024-042 雅本化学股份有限公司 关于终止部分募集资金投资项目并将剩余募集资金永久补 充流动资金的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据《深圳证券交易所创业板股票上市规则（2024 年修订）》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2023 年 12 月修订）》及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求（2022 年修订）》等有关规定，雅本化学股份有限公司(以下简称"雅 本化学"或"公司")于 2024 年 5 月 15 日召开第五届董事会第十八次（临时） 会议，审议通过了《关于终止部分募集资金投资项目并将剩余募集资金永久补 充流动资金的议案》。本次议案尚需提交公司股东大会审议。现将相关事项公 告如下： 一、募集资金投资项目基本情况 经中国证券监督管理委员会《关于核准雅本化学股份有限公司非公开发行 股票的批复》"证监许可[2017]1091 号"的核准，公司共计向特定对象非公开发 行人民币普通股（A 股）105,231, ...

证券代码：300261 证券简称：雅本化学 公告编号：2024-039 雅本化学股份有限公司 第五届董事会第十八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")第五届董事会第十八次（临时）会 议于 2024 年 5 月 15 日上午 10:30 以现场结合通讯方式召开，会议通知已于 2024 年 5 月 10 日以邮件方式送达全体董事和监事。本次会议应出席董事 8 名，实际出席会 议董事 8 名。会议由公司董事长蔡彤先生主持，公司监事及其他高级管理人员列席 了会议。本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 三、审议通过了《关于召开2024年第二次临时股东大会的议案》 经审议，董事会一致同意于2024年5月31日召开2024年第二次临时股东大会。详 见中国证监会指定信息披露网站刊登的公告。 经审议，董事会一致同意公司终止募集资金投资项目"滨海基地新增生产线项 目"并将该募投项目剩余募集资金（包括现金管理收益及利息收入并扣除银行手续 费支出等，具体金额以资金转出当日银行结算余额为 ...

雅本化学股份有限公司 章 程 二〇二四年五月 1 | | | | 第一章 | 总 | 则 1 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 2 | | 第一节 | | 股份发行 2 | | 第二节 | | 股份增减和回购 3 | | 第三节 | | 股份转让 4 | | 第四章 | | 股东和股东大会 5 | | 第一节 | | 股 东 5 | | 第二节 | | 股东大会的一般规定 7 | | 第三节 | | 股东大会的召集 10 | | 第四节 | | 股东大会的提案与通知 11 | | 第五节 | | 股东大会的召开 13 | | 第六节 | | 股东大会的表决和决议 15 | | 第五章 | | 董事会 19 | | 第一节 | | 董 事 19 | | 第二节 | | 董事会 22 | | 第六章 | | 总经理及其他高级管理人员 26 | | 第七章 | | 监事会 28 | | 第一节 | | 监 事 28 | | 第二节 | | 监事会 29 | | 第八章 | | 财务会计制度、利润分配和审计 31 | | 第一节 | | ...

| 原条款 | 修订后条款 | | --- | --- | | 第一百五十五条 公司股东大会对利润 | 第一百五十五条 公司股东大会对利润 | | 分配方案作出决议后，公司董事会须 | 分配方案作出决议后，或公司董事会 | | 在股东大会召开后 2 个月内完成股利 | 根据年度股东大会审议通过的下一年 | | （或股份）的派发事项。 | 中期分红条件和上限制定具体方案 | | | 后，须在 个月内完成股利（或股 2 | | | 份）的派发事项。 | | 第一百五十六条（二）公司现金方式 | 第一百五十六条 （二）公司现金方式 | | 分红的具体条件和比例：公司该年度 | 分红的具体条件和比例：公司累计未 | | 实现的可分配利润（即公司弥补亏 | 分配利润为正值，且现金流充裕，实 | | 损、提取公积金后所余的税后利润） | 施现金分红不会影响公司后续持续经 | | 为正值、且现金流充裕，实施现金分 | 营；且审计机构对公司的该年度财务 | | 红不会影响公司后续持续经营；且审 | 报告出具标准无保留意见的审计报 | | 计机构对公司的该年度财务报告出具 | 告，则公司应当进行现金分红；公司 | | 标准无保 ...

中国国际金融股份有限公司 关于雅本化学股份有限公司终止部分募投项目 并将该部分募集资金永久补充流动资金的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为雅 本化学股份有限公司（以下简称"雅本化学"或"公司"）2017 年非公开发行股票 的保荐机构，根据《证券发行上市保荐业务管理办法（2023 年修订）》《深圳证 券交易所创业板股票上市规则（2024 年修订）》《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求（2022 年修订）》和《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2023 年 12 月 修订）》等有关规定的要求，等相关法律、法规和规范性文件的要求，对雅本化 学终止部分募投项目并将该部分募集资金永久补充流动资金进行了审慎核查， 具体情况如下： 一、募集资金投资项目基本情况 经中国证券监督管理委员会《关于核准雅本化学股份有限公司非公开发行 股票的批复》"证监许可[2017]1091 号"的核准，公司共计向特定对象非公开发 行人民币普通股（A 股）105,231,796 股，共计募集人民币 867,109,999.04 元， ...

Financial Performance - The company reported a net profit attributable to shareholders of -82,293,808.08 RMB for the year 2023, indicating a significant decline compared to the previous year[5]. - The decline in revenue and net profit was primarily due to a cyclical downturn in the agricultural chemical industry, customer inventory adjustments, and a notable reduction in orders for pharmaceutical business[5]. - The company's operating revenue for 2023 was ¥1,278,848,252, a decrease of 36.09% compared to ¥2,000,975,899 in 2022[23]. - The net profit attributable to shareholders for 2023 was ¥82,293,808, representing a decline of 140.55% from ¥181,849,264 in 2022[23]. - The net cash flow from operating activities was negative at ¥25,854,785, a decrease of 131.89% compared to ¥81,067,227 in 2022[23]. - The basic and diluted earnings per share for 2023 were both -¥0.0862, down from ¥0.2126 in 2022, marking a decline of 140.55%[23]. - The company reported a quarterly operating revenue of ¥478,738,678 in Q1, which decreased to ¥178,273,401 in Q4[29]. - The net profit attributable to shareholders in Q4 was -¥158,951,772, following positive profits in the first three quarters[29]. Strategic Initiatives - The company emphasizes its commitment to research and development, particularly in the pharmaceutical sector, to enhance its product offerings[5]. - The company continues to focus on its main business areas and is exploring opportunities for market expansion and strategic partnerships[5]. - The company has set a revenue guidance of 1.5 billion yuan for the next fiscal year, representing a 20% growth compared to the previous year[49]. - The company is actively pursuing market expansion, targeting new regions in Asia and Europe, aiming for a 30% increase in market penetration by 2025[49]. - Strategic partnerships with Fortune 500 companies have been established, enhancing supply chain stability and increasing production capacity[49]. - The company plans to enhance its manufacturing capabilities through potential acquisitions, targeting a 15% increase in production efficiency[49]. Research and Development - The company operates four R&D centers focusing on technology and product innovation, optimizing processes, and transforming results[42]. - The company has invested 200 million yuan in R&D for new technologies, aiming to improve product efficacy and reduce environmental impact[49]. - The company's R&D investment has increased from 0.15 million to 1.2 million in 2023, demonstrating a commitment to continuous innovation[57]. - The company is focusing on increasing its market share in the plant growth regulator category, with products like 15% and 25% paclobutrazol showing promising growth potential[51][52]. - Ongoing research and development efforts are directed towards enhancing the effectiveness of existing products and exploring new active ingredients[50]. Environmental Commitment - The company is committed to sustainability, with initiatives aimed at reducing carbon emissions by 25% over the next five years[49]. - The company has established comprehensive wastewater and waste gas treatment facilities to ensure compliance with environmental standards, aiming to minimize negative ecological impacts[182]. - The company reported a total discharge of 3.32213 tons of COD, with a maximum concentration of 133 mg/l, during the reporting period[184]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[182]. - The company has implemented a compliance evaluation process to adapt to new environmental regulations and standards[182]. Corporate Governance - The company held four shareholder meetings in 2023, ensuring equal rights for shareholders and compliance with legal procedures[135]. - The board of directors consists of 9 members, including 3 independent directors, and operates in accordance with legal and regulatory requirements[136]. - The company has established a fair and transparent performance evaluation and incentive mechanism, promoting effective management and employee motivation[139]. - The company actively engages with stakeholders to respect and protect their legitimate rights and interests, fostering balanced development[139]. - The company is committed to maintaining high standards of corporate governance and transparency in its operations[148]. Market Outlook - The global pesticide market is projected to grow at a CAGR of 5.6% from 2023 to 2030, driven by increasing food security concerns and regulatory pressures[38]. - The Chinese chemical raw materials market is expected to reach ¥473.6 billion in revenue by 2023, indicating a recovery trend in the industry[39]. - The company plans to enhance production capacity utilization in 2024, focusing on flexible production and green sustainable development[61]. - The company aims to achieve a comprehensive technology innovation system from small-scale testing to commercial production[58]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic investments and technology development[114].

Financial Performance - The company's revenue for Q1 2024 was ¥219,942,064.63, a decrease of 54.06% compared to ¥478,738,677.64 in the same period last year[5] - The net loss attributable to shareholders was ¥45,576,667.50, representing a decline of 185.65% from a profit of ¥53,215,317.80 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0475, a decrease of 185.28% from ¥0.0557 in the same period last year[5] - The net profit for the first quarter of 2024 was -44,286,323.71 CNY, compared to a net profit of 52,294,452.98 CNY in the same period last year, representing a significant decline[20] - The company reported a total comprehensive income of -57,137,857.45 CNY for the first quarter, compared to 57,873,413.39 CNY in the same quarter last year[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥6,343,271.16, down 94.09% from ¥107,265,279.07 in Q1 2023[5] - The cash and cash equivalents at the end of the period were 314,720,829.76 CNY, down from 451,657,264.02 CNY at the end of the previous year, a decrease of approximately 30.3%[24] - The company incurred a loss of -50,531,001.17 CNY in operating profit, contrasting with an operating profit of 61,431,600.21 CNY in the same quarter last year[20] - The company's investment activities resulted in a net cash outflow of -34,739,365.09 CNY, compared to -59,915,264.87 CNY in the previous year, showing an improvement in cash flow management[24] - The financing activities generated a net cash inflow of 117,285,445.73 CNY, significantly higher than 25,835,029.21 CNY in the same period last year, indicating increased financing efforts[24] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥4,192,018,181.26, an increase of 1.13% from ¥4,145,222,725.41 at the end of the previous year[5] - Total liabilities increased to CNY 1,777,396,469.51 from CNY 1,717,475,770.19, marking a rise of 3.5%[18] - The company's equity attributable to shareholders decreased to CNY 2,258,389,004.97 from CNY 2,274,817,267.89, a decline of 0.7%[18] Research and Development - The company's R&D expenses decreased by 30.36% to ¥19,379,345.49 from ¥27,826,005.82 in Q1 2023[9] - Research and development expenses for Q1 2024 were CNY 19,379,345.49, down 30.4% from CNY 27,826,005.82 in the previous year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,029[11] - Ningbo Yabao Holdings holds 26.75% of shares, totaling 257,729,839 shares[11] - The company has a new employee stock ownership plan for 2023, holding 8,623,900 shares[11] - The company has 6.75% of shares held by foreign individual shareholder Wang Xinya, totaling 65,000,350 shares[11] - The company has 2.91% of shares held by Zhang Yuxin, totaling 28,010,000 shares[11] - The company has 2.53% of shares held by Cai Tong, totaling 24,376,051 shares, with 18,282,038 shares under pledge[11] - The company has 0.73% of shares held by Jin Xiangguo and Liao Guopei, each totaling 7,000,000 shares[11] Legal Matters - The company has 43 ongoing lawsuits with a total amount involved of 2,593,035,000 CNY, which will not significantly impact financial statements[13] - The company has paid 2,383,525.20 CNY in relation to a judgment that has come into effect[13] Investment Income - The company reported a significant decrease in investment income, down 50.03% to ¥941,210.32 from ¥1,883,366.72 in the same period last year[9] - The company reported an investment income of CNY 941,210.32, a decrease of 50.0% compared to CNY 1,883,366.72 in the same period last year[19] Fair Value Changes - The company experienced a 240.07% decline in fair value changes, reporting a loss of ¥6,655,670.00 compared to a gain of ¥4,751,745.00 in the previous year[9] Accounts Receivable and Inventory - Accounts receivable decreased to CNY 511,030,145.46 from CNY 573,663,679.59, a decline of 10.9%[16] - Inventory increased to CNY 614,976,811.90 from CNY 587,282,262.37, reflecting a rise of 4.7%[16]

雅本化学股份有限公司 独立董事2023年度述职报告 各位股东及股东代表： 本人作为雅本化学股份有限公司（以下简称"公司"）的独立董事，在任职 期间严格按照《公司法》《证券法》《上市公司独立董事规则》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—— 创业板上市公司规范运作》《公司章程》《独立董事制度》等相关法律法规， 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用， 努力维护公司股东，特别是中小股东的合法权益。现将2023年度本人的工作情 况报告如下： 一、 独立董事基本情况及独立性自查情况 饶艳超女士，中国国籍，无永久境外居留权，女，汉族，1973年生，博士。 历任南昌大学经济系助教，上海财经大学会计学院讲师，福然德股份有限公司 独立董事，深圳市宇顺电子股份有限公司独立董事，浙江瑞晟智能科技股份有 限公司独立董事。现任上海财经大学副教授，雅本化学股份有限公司独立董事， 上海新诤信知识产权服务股份有限公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， ...